Etilevodopa
Based on 1 Customer Validation
Etilevodopa (L-Dopa ethyl ester), an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.00%
- CAS 番号: 37178-37-3
- 分子式: C11H15NO4
- 分子量:225.24
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Metabolism/Protease Compound Library
HY-L012
-
Neuronal Signaling Compound Library
HY-L013
-
Clinical Compound Library
HY-L026
-
Drug Repurposing Compound Library
HY-L035
-
Neurotransmitter Receptor Compound Library
HY-L062
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Drug Metabolite Library
HY-L098
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Dopamine Receptor Compound Library
HY-L165
-
Bioactive Compound Library Max
HY-L181
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Dopamine Receptor アイソフォーム固有の製品をすべて表示
More
生物活性
Etilevodopa (L-Dopa ethyl ester) passes unchanged through the stomach to the duodenum, where it is rapidly hydrolyzed by local esterases to Levodopa and ethanol, and is subsequently absorbed into the blood stream as Levodopa[1].
Compared with standard Levodopa, Etilevodopa has greater solubility in the stomach, faster passage to the small intestine, and a shortened time to maximum Levodopa concentration[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 37178-37-3
-
性状 Solid
-
分子量 225.24
-
分子式 C11H15NO4
-
Color White to off-white
-
SMILES
N[C@H](C(OCC)=O)CC1=CC=C(C(O)=C1)O
-
別名
L-DOPA ethyl ester; Levodopa ethyl ester
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
H2O : 12 mg/mL (53.28 mM; Need ultrasonic and warming)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (271 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Djaldetti R, et al. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. Clin Neuropharmacol. 2003 Nov-Dec;26(6):322-6. [Content Brief]
[2]. Blindauer K, et al. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006 Feb;63(2):210-6. [Content Brief]
[3]. Haddad F, et al. Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease. Molecules. 2017 Dec 25;23(1). pii: E40. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 4.4397 mL | 22.1985 mL | 44.3971 mL | 110.9927 mL |
| 5 mM | 0.8879 mL | 4.4397 mL | 8.8794 mL | 22.1985 mL | |
| 10 mM | 0.4440 mL | 2.2199 mL | 4.4397 mL | 11.0993 mL | |
| 15 mM | 0.2960 mL | 1.4799 mL | 2.9598 mL | 7.3995 mL | |
| 20 mM | 0.2220 mL | 1.1099 mL | 2.2199 mL | 5.5496 mL | |
| 25 mM | 0.1776 mL | 0.8879 mL | 1.7759 mL | 4.4397 mL | |
| 30 mM | 0.1480 mL | 0.7400 mL | 1.4799 mL | 3.6998 mL | |
| 40 mM | 0.1110 mL | 0.5550 mL | 1.1099 mL | 2.7748 mL | |
| 50 mM | 0.0888 mL | 0.4440 mL | 0.8879 mL | 2.2199 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Etilevodopa 関連分類
HY-116016 関連分類
Powered by Bioz